THU0369 Secukinumab 150mg Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis With High Retention Rate: 3-Year Results From Phase Iii Trial, Measure 2

doi 10.1136/annrheumdis-2017-eular.1295
Full Text
Abstract

Available in full text

Date
Authors
Publisher

BMJ Publishing Group Ltd and European League Against Rheumatism

Related search

Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Psoriatic Arthritis: Final 5‐year Results From the Phase 3 FUTURE 1 Study

ACR Open Rheumatology
2019English

Efficacy, Safety, and Tolerability of Secukinumab in Patients With Active Ankylosing Spondylitis: A Randomized, Double-Blind Phase 3 Study, MEASURE 3

Arthritis Research & Therapy
2017English

FRI0494 Secukinumab Provides Rapid and Sustained Pain Relief in Psoriatic Arthritis: 2-Year Results From the Future 2 Study

2017English

Correction To: Secukinumab: A Review in Ankylosing Spondylitis

Drugs
Pharmacology
2019English

The High Prevalence of Infections and Allergic Symptoms in Patients With Ankylosing Spondylitis Is Associated With Clinical Symptoms

Clinical Rheumatology
MedicineRheumatology
2006English

The Advent of IL-17A Blockade in Ankylosing Spondylitis: Secukinumab, Ixekizumab and Beyond

Expert Review of Clinical Immunology
AllergyImmunology
2019English

Sustained Response to Anakinra in Ankylosing Spondylitis

Rheumatology
RheumatologyPharmacology
2007English

Cost-Effectiveness Analysis of Secukinumab in Ankylosing Spondylitis: A Canadian Perspective

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2017English

Real-World Data on Secukinumab Use for Psoriatic Arthritis and Ankylosing Spondylitis

Therapeutic Advances in Musculoskeletal Disease
RheumatologyOrthopedicsSports Medicine
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy